An enantiomer of (±)-atenolol
Related Products
Enantiomer(s)
17250(±)-Atenolol
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

(+)-Atenolol

Item No. 18623

Technical Information
Formal Name
4-[(2R)-2-hydroxy-3-[(1-methylethyl)amino]propoxy]-benzeneacetamide
CAS Number
56715-13-0
Synonyms
  • (R)-Atenolol
Molecular Formula
C14H22N2O3
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 20 mg/mlDMSO: 15 mg/mlEthanol: 5 mg/mlPBS (pH 7.2): 1 mg/ml
λmax
226, 276 nm
SMILES
NC(CC1=CC=C(OC[C@H](O)CNC(C)C)C=C1)=O
InChi Code
InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)/t12-/m1/s1
InChi Key
METKIMKYRPQLGS-GFCCVEGCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    (+)-Atenolol is an enantiomer of the β1-adrenergic receptor (β1-AR) antagonist (±)-atenolol (Item No. 17250).1 (+)-Atenolol inhibits radioligand binding to β-ARs on sarcolemma-enriched membranes (Ki = 8.61 µM). Unlike (–)-atenolol and (±)-antenolol, (+)-atenolol has no effect on blood pressure in spontaneously hypertensive rats.2,3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Stoschitzky, K., Egginger, G., Zernig, G., et alStereoselective features of (R)- and (S)-atenolol: Clinical pharmacological, pharmacokinetic, and radioligand binding studies. Chirality 5(1), 15-19 (1993).

    2. Richer, C., Boissier, J.R., and Giudicelli, J.F. Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats. Eur. J. Pharmacol. 47(4), 393-400 (1978).

    3. Pearson, A.A., Gaffney, T.E., Walle, T., et alA stereoselective central hypotensive action of atenolol. J. Pharmacol. Exp. Ther. 250(3), 759-763 (1989).